NIPH Clinical Trials Search

An observational study to evaluate the impact of treatment strategies and patient-related factors on survival in patients with newly diagnosed Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomonocytic Leukemia (CMML) at institutions participating in the Japan Adult Leukemia Study Group (JALSG)

Basic Information

Recruitment status	Pending
Health condition(s) or Problem(s) studied	Patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) diagnosed at institutions participating in the Japan Adult Leukemia Study Group (JALSG).
Date of first enrollment	2026/06/01
Target sample size	2000
Countries of recruitment	Japan
Study type	Observational
Intervention(s)

Outcome(s)

Primary Outcome

Overall survival of patients with AML, MDS, or CMML

Secondary Outcome

Initial treatment efficacy and remission rates by treatment type for AML, MDS, and CMML Relapse-free survival by AML, MDS, and CMML Impact of the use of new drugs on survival rates for AML, MDS, and CMML Impact of the use of supportive care medications on survival rates for AML, MDS, and CMML Evaluation of causes of death Survival rates following allogeneic hematopoietic stem cell transplantation, and the relationship between transplantation methods and relapse-free and graft-versus-host disease (GVHD)-free survival rates Evaluation of transplantation-related complications in allogeneic hematopoietic stem cell transplantation cases Analysis of risk factors affecting overall survival (OS) (impact of patient background, comorbidities, and concomitant medications on treatment outcomes) Impact of genetic information on prognosis

Key inclusion & exclusion criteria

Age minimum	16years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	If the principal investigator or a co-investigator determines that participation in this study is inappropriate.